UOC
RNAM

UBS O'Connor’s Avidity Biosciences RNAM Stock Holding History

UBS O'Connor’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$268M Buy
+3,716,597
New +$240M 7.14% 5

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS O'Connor's RNAM Position: Q4 2025 in Review

UBS O'Connor opened a new position in Avidity Biosciences (RNAM) in Q4 2025: 3,716,597 shares worth $268M. The stake represents 7.14% of the portfolio and ranks #5 among its holdings.

343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • UBS O'Connor held 3,716,597 shares of Avidity Biosciences worth $268M as of Q4 2025.
  • Avidity Biosciences was a new UBS O'Connor position in Q4 2025.
  • Avidity Biosciences made up 7.14% of UBS O'Connor's portfolio in Q4 2025, its #5 holding.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on UBS O'Connor's 13F filing for Q4 2025, filed 13 Feb 2026.